Evidence map›Paper›PMID 25952684›Full record

ArticleMovement disorders : official journal of the Movement Disorder Society2015

Disclosure of research results in genetic studies of Parkinson's disease caused by LRRK2 mutations.

Claustre Pont-Sunyer, Susan Bressman, Deborah Raymond, Amanda Glickman, Eduardo Tolosa, Rachel Saunders-Pullman

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Movement disorders : official journal of the Movement Disorder Society, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 12 citations in OpenAlex.

  1. Genetic Testing in Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2023
    Article
  2. Article
  3. Cautionary optimism: caffeine and Parkinson's disease risk.Journal of clinical movement disorders · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Claustre Pont-SunyerParkinson Disease and Movement Disorders Unit, Neurology Service, IDIBAPS, CIBERNED, Universitat de Barcelona, Hospital Clínic, Barcelona, Catalonia, Spain.
Susan BressmanDepartment of Neurology, Mount Sinai Beth Israel Medical Center, New York, NY, USA.
Deborah RaymondDepartment of Neurology, Mount Sinai Beth Israel Medical Center, New York, NY, USA.
Amanda GlickmanDepartment of Neurology, Mount Sinai Beth Israel Medical Center, New York, NY, USA.
Eduardo TolosaParkinson Disease and Movement Disorders Unit, Neurology Service, IDIBAPS, CIBERNED, Universitat de Barcelona, Hospital Clínic, Barcelona, Catalonia, Spain.
Rachel Saunders-PullmanDepartment of Neurology, Mount Sinai Beth Israel Medical Center, New York, NY, USA.
Mount Sinai Beth Israel · USBiomedical Research Networking Center on Neurodegenerative Diseases · ESUniversitat de Barcelona · ES

Funding

Phenotypic Spectrum of LRRK2 MutationsK02NS073836 · NINDS · BETH ISRAEL MEDICAL CTR (NEW YORK) · PI SAUNDERS-PULLMAN, RACHEL · 2011 to 2015
$879k
NINDS NIH HHS K02 NS073836NINDS NIH HHS NS073836
6 · The paper itself

Abstract

With the advent of large genetic studies examining both symptomatic and asymptomatic individuals, whether and how to disclose genetic research results have become pressing questions. The need is particularly acute in the case of LRRK2 research: Movement centers worldwide are recruiting cohorts of individuals with Parkinson's disease (PD) and their family members, including asymptomatic carriers. Clinical features and treatment are complex and evolving, and disclosure policies vary at different sites and have been modified during the course of some studies. We present the major ethical principles of autonomy, beneficence, nonmaleficence, and honesty that should guide disclosure policies in studies of families with LRRK2 mutations. We make recommendations regarding genetic counseling, policies of either active or passive disclosure, responsibilities of funders to budget for genetic counseling, clinical genetic testing where locally required for disclosure, and aspects of study design to avoid mandatory disclosure whenever feasible. © 2015 International Parkinson and Movement Disorder Society.

Indexed as

Biomedical ResearchGenetic TestingHumansLeucine-Rich Repeat Serine-Threonine Protein Kinase-2MutationParkinson DiseaseProtein Serine-Threonine KinasesTruth DisclosureLeucine-Rich Repeat Serine-Threonine Protein Kinase-2LRRK2 protein, humanProtein Serine-Threonine Kinasesclinical researchdisclosureethicsgenetic counselingLRRK2 mutationParkinson's disease

Identifiers

PMID25952684
PMCPMC4478096
OpenAlexW1896293898

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.